19 June 2013
Keywords: Merck & Co, Daxas, COPD, UK, NICE, Clinical trial, Cost-effectiveness
Article | 08 December 2011
UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final draft guidance on the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 December 2011
18 June 2013
© 2013 thepharmaletter.com